A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis.

Ida Vittrup,Niels Steen Krogh,Henrik Hedegaard Pliess Larsen,Jesper Elberling,Lone Skov,Kristina Sophie Ibler,Gregor B E Jemec,Charlotte G Mortz,Rasmus Overgaard Bach,Carsten Bindslev-Jensen,Maiken Glud Dalager,Alexander Egeberg,Tove Agner,Mette Deleuran,Christian Vestergaard,Jacob Pontoppidan Thyssen

Journal of the European Academy of Dermatology and Venereology : JEADV（2023）

引用 3|浏览41

暂无评分

摘要

While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要